Mathematical modeling of the in vitro hepatic disposition of mycophenolic acid and its glucuronide in sandwich-cultured human hepatocytes.

In recent years, it has become increasingly important to test the safety of circulating metabolites of novel drugs as part of drug discovery and development programs. Accordingly, it is essential to develop suitable methods for identifying the major metabolites and their disposition in animal species and in humans. Mycophenolic acid (MPA), a selective inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor, is metabolized by glucuronidation and enterohepatic circulation of MPA-glucuronides is an important factor in the continuous systemic exposure of MPA. In humans, about 90% of the administered MPA dose is finally excreted as MPA phenyl-glucuronide (MPAG) in urine. Notably, the plasma concentration of MPAG is much higher than that of MPA. These factors suggest that, after its formation in hepatocytes, MPAG is excreted into bile and is also transported across the basolateral membrane to enter the circulation. In the present study, we performed metabolic/hepatobiliary transport studies of MPA and MPAG using sandwich-cultured human hepatocytes (SCHH) and constructed mathematical models of their hepatic disposition. We also performed vesicular transport studies to identify which human multidrug resistance-associated proteins (MRPs) are involved in the transport of MPAG from hepatocytes. MPAG was a preferred substrate for the biliary excretion transporter MRP2 and the hepatic basolateral transporters MRP3 and MRP4 in conventional and metabolic/hepatobiliary transport studies using SCHH and vesicular transport studies using human MRP-expressing membrane vesicles. The resulting mathematical model suggested that the basolateral transport plays an important role in the hepatic disposition of MPAG formed in hepatocytes. Our findings suggest that mathematical modeling of metabolic/hepatobiliary transport studies using SCH will provide useful information for determining the fate of metabolites formed in hepatocytes.

[1]  K. Brouwer,et al.  In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development , 2013, Clinical pharmacology and therapeutics.

[2]  P. Annaert,et al.  Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity , 2013, Expert opinion on drug metabolism & toxicology.

[3]  I. Tamai,et al.  Evaluation of Hepatic Disposition of Paroxetine Using Sandwich-Cultured Rat and Human Hepatocytes , 2013, Drug Metabolism and Disposition.

[4]  F. Akhlaghi,et al.  Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus , 2013, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  T. Nakanishi,et al.  Application of quantitative time-lapse imaging (QTLI) for evaluation of Mrp2-based drug-drug interaction induced by liver metabolites. , 2012, Toxicology and applied pharmacology.

[6]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[7]  Yongling Xiao,et al.  Differential Modulation of Cytochrome P450 Activity and the Effect of 1-Aminobenzotriazole on Hepatic Transport in Sandwich-Cultured Human Hepatocytes , 2012, Drug Metabolism and Disposition.

[8]  G. Keating,et al.  Enteric-Coated Mycophenolate Sodium , 2012, Drugs.

[9]  T. Horie,et al.  Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes. , 2011, Biochemical and biophysical research communications.

[10]  K. Maeda,et al.  Culture Period-Dependent Changes in the Uptake of Transporter Substrates in Sandwich-Cultured Rat and Human Hepatocytes , 2011, Drug Metabolism and Disposition.

[11]  J. Sahi,et al.  Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  T. Nakanishi,et al.  Quantitative Time-Lapse Imaging-Based Analysis of Drug-Drug Interaction Mediated by Hepatobiliary Transporter, Multidrug Resistance-Associated Protein 2, in Sandwich-Cultured Rat Hepatocytes , 2011, Drug Metabolism and Disposition.

[13]  A. Prémaud,et al.  Large Scale Analysis of Routine Dose Adjustments of Mycophenolate Mofetil Based on Global Exposure in Renal Transplant Patients , 2011, Therapeutic drug monitoring.

[14]  D. B. Duignan,et al.  Characterization of Digoxin Uptake in Sandwich-Cultured Human Hepatocytes , 2011, Drug Metabolism and Disposition.

[15]  S. O. Mueller,et al.  Development of an in vitro liver toxicity prediction model based on longer term primary rat hepatocyte culture. , 2008, Toxicology letters.

[16]  M. Fromm,et al.  SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. , 2010, Pharmacogenomics.

[17]  L. Melvin,et al.  Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. , 2010, Canadian journal of physiology and pharmacology.

[18]  Y. Lai,et al.  Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. , 2010, Molecular pharmaceutics.

[19]  K. Brouwer,et al.  Influence of seeding density and extracellular matrix on bile Acid transport and mrp4 expression in sandwich-cultured mouse hepatocytes. , 2010, Molecular pharmaceutics.

[20]  C. Staatz,et al.  Pharmacogenetic influences on mycophenolate therapy. , 2010, Pharmacogenomics.

[21]  K. Brouwer,et al.  Hepatobiliary Disposition of Troglitazone and Metabolites in Rat and Human Sandwich-Cultured Hepatocytes: Use of Monte Carlo Simulations to Assess the Impact of Changes in Biliary Excretion on Troglitazone Sulfate Accumulation , 2010, Journal of Pharmacology and Experimental Therapeutics.

[22]  K. Giacomini,et al.  The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics , 2010, Clinical pharmacology and therapeutics.

[23]  Jennifer Q. Dong,et al.  Glucuronidation and Covalent Protein Binding of Benoxaprofen and Flunoxaprofen in Sandwich-Cultured Rat and Human Hepatocytes , 2009, Drug Metabolism and Disposition.

[24]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[25]  S. O. Mueller,et al.  Serum-free collagen sandwich cultures of adult rat hepatocytes maintain liver-like properties long term: a valuable model for in vitro toxicity and drug-drug interaction studies. , 2009, Chemico-biological interactions.

[26]  Y. Kagawa,et al.  Impact of Calcineurin Inhibitors on Urinary Excretion of Mycophenolic Acid and Its Glucuronide in Kidney Transplant Recipients , 2009, Journal of clinical pharmacology.

[27]  Shufeng Zhou,et al.  Mechanism‐Based Enterohepatic Circulation Model of Mycophenolic Acid and Its Glucuronide Metabolite: Assessment of Impact of Cyclosporine Dose in Asian Renal Transplant Patients , 2009, Journal of clinical pharmacology.

[28]  Y. Sugiyama,et al.  Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3 , 2008, Pharmacogenetics and genomics.

[29]  Rikiya Ohashi,et al.  Effect of Plasma Protein Binding on in Vitro-in Vivo Correlation of Biliary Excretion of Drugs Evaluated by Sandwich-Cultured Rat Hepatocytes , 2008, Drug Metabolism and Disposition.

[30]  C. Guillemette,et al.  The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[31]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients , 2007, Clinical pharmacokinetics.

[32]  D. Keppler,et al.  Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system , 2006, Neuroscience.

[33]  V. Armstrong,et al.  Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients , 2006, Clinical pharmacology and therapeutics.

[34]  J. D. de Fijter,et al.  Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. , 2005, British journal of clinical pharmacology.

[35]  Hanneke van Helvoort,et al.  THE USE OF SANDWICH-CULTURED RAT HEPATOCYTES TO DETERMINE THE INTRINSIC CLEARANCE OF COMPOUNDS WITH DIFFERENT EXTRACTION RATIOS: 7-ETHOXYCOUMARIN AND WARFARIN , 2005, Drug Metabolism and Disposition.

[36]  K. Brouwer,et al.  P-glycoprotein Expression, Localization, and Function in Sandwich-Cultured Primary Rat and Human Hepatocytes: Relevance to the Hepatobiliary Disposition of a Model Opioid Peptide , 2004, Pharmaceutical Research.

[37]  T. Hirano,et al.  Cyclosporin A, but Not Tacrolimus, Inhibits the Biliary Excretion of Mycophenolic Acid Glucuronide Possibly Mediated by Multidrug Resistance-Associated Protein 2 in Rats , 2004, Journal of Pharmacology and Experimental Therapeutics.

[38]  M. Fromm,et al.  Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver , 2003, Journal of Pharmacology and Experimental Therapeutics.

[39]  Yau Yi Lau,et al.  Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[40]  N. Perico,et al.  Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients , 2001, Clinical transplantation.

[41]  J. Miners,et al.  The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. , 2001, British journal of clinical pharmacology.

[42]  R. Tukey,et al.  Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes , 2001, British journal of pharmacology.

[43]  V. Armstrong,et al.  Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. , 1999, Clinical chemistry.

[44]  V. Armstrong,et al.  Identification of glucoside and carboxyl‐linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil , 1999, British journal of pharmacology.

[45]  W. Weimar,et al.  Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  A. Nicholls,et al.  Clinical Pharmacokinetics of Mycophenolate Mofetil , 1998, Clinical pharmacokinetics.

[47]  R. Pichlmayr,et al.  Drug metabolism in hepatocyte sandwich cultures of rats and humans. , 1997, Biochemical pharmacology.

[48]  M. Hale,et al.  Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration , 1996, Journal of clinical pharmacology.

[49]  K. Pang,et al.  Effect of diffusional barriers on drug and metabolite kinetics. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[50]  W. Cherry,et al.  Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. , 1984, Drug metabolism and disposition: the biological fate of chemicals.